News Image

First Patients Enrolled at UHealth – University of Miami in Aclarion’s Pivotal CLARITY Trial

Provided By GlobeNewswire

Last update: Sep 25, 2025

BROOMFIELD, Colo., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that the UHealth – University of Miami Health System and the Miller School of Medicine enrolled its first two patients in the CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial. The pivotal CLARITY study is designed to demonstrate Nociscan’s clinical and economic value in spine surgery.

Read more at globenewswire.com

ACLARION INC -CW27

NASDAQ:ACONW (10/14/2025, 8:00:00 PM)

After market: 0.0562 0 (-1.58%)

0.0571

-0.05 (-44.62%)


ACLARION INC

NASDAQ:ACON (10/14/2025, 8:00:00 PM)

After market: 8.63 -0.32 (-3.58%)

8.95

-0.74 (-7.64%)



Find more stocks in the Stock Screener

Follow ChartMill for more